Interpace Diagnostics (IDXG) Tops Q2 EPS by 2c

Interpace Diagnostics (NASDAQ: IDXG) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $5.04 million.

For earnings history and earnings-related data on Interpace Diagnostics (IDXG) click here.

You May Also Be Interested In

• Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Air Products & Chemicals Inc. (APD) PT Raised to $329 at Argus